Re: [urn] Request for a Namespace Registration for Unique (Vaccination) Certificate Identifier

Dirk-Willem van Gulik <dirkx@webweaving.org> Thu, 12 August 2021 08:20 UTC

Return-Path: <dirkx@webweaving.org>
X-Original-To: urn@ietfa.amsl.com
Delivered-To: urn@ietfa.amsl.com
Received: from localhost (localhost [127.0.0.1]) by ietfa.amsl.com (Postfix) with ESMTP id 60CE03A3C29 for <urn@ietfa.amsl.com>; Thu, 12 Aug 2021 01:20:31 -0700 (PDT)
X-Virus-Scanned: amavisd-new at amsl.com
X-Spam-Flag: NO
X-Spam-Score: -1.898
X-Spam-Level:
X-Spam-Status: No, score=-1.898 tagged_above=-999 required=5 tests=[BAYES_00=-1.9, HTML_MESSAGE=0.001, SPF_HELO_NONE=0.001, SPF_PASS=-0.001, URIBL_BLOCKED=0.001] autolearn=ham autolearn_force=no
Received: from mail.ietf.org ([4.31.198.44]) by localhost (ietfa.amsl.com [127.0.0.1]) (amavisd-new, port 10024) with ESMTP id ZMUvljTcr_co for <urn@ietfa.amsl.com>; Thu, 12 Aug 2021 01:20:26 -0700 (PDT)
Received: from weser.webweaving.org (weser.webweaving.org [148.251.234.232]) (using TLSv1.2 with cipher ECDHE-RSA-AES256-GCM-SHA384 (256/256 bits)) (No client certificate requested) by ietfa.amsl.com (Postfix) with ESMTPS id D750D3A3C25 for <urn@ietf.org>; Thu, 12 Aug 2021 01:20:24 -0700 (PDT)
Received: from smtpclient.apple (94-210-134-94.cable.dynamic.v4.ziggo.nl [94.210.134.94]) (authenticated bits=0) by weser.webweaving.org (8.16.1/8.16.1) with ESMTPSA id 17C8InbD043309 (version=TLSv1.2 cipher=ECDHE-RSA-AES256-GCM-SHA384 bits=256 verify=NO); Thu, 12 Aug 2021 10:18:50 +0200 (CEST) (envelope-from dirkx@webweaving.org)
X-Authentication-Warning: weser.webweaving.org: Host 94-210-134-94.cable.dynamic.v4.ziggo.nl [94.210.134.94] claimed to be smtpclient.apple
From: Dirk-Willem van Gulik <dirkx@webweaving.org>
Message-Id: <5687DB34-D448-489D-BBB9-1D5A2CEEB0D2@webweaving.org>
Content-Type: multipart/alternative; boundary="Apple-Mail=_7E3D9DD3-D0F0-4D0D-8B0A-1A7DABDEDB91"
Mime-Version: 1.0 (Mac OS X Mail 14.0 \(3654.100.0.2.22\))
Date: Thu, 12 Aug 2021 10:18:47 +0200
In-Reply-To: <B785B482-9469-4BC7-BF77-58B603B30455@eguy.org>
Cc: Peter Saint-Andre <stpeter@mozilla.com>, "urn@ietf.org" <urn@ietf.org>, the eHEALTH-NETWORK Secretariat <eHEALTH-NETWORK@ec.europa.eu>
To: Ed Guy <edguy@eguy.org>
References: <3053F7E9-7C6A-4AAB-AC87-63DC1D6A58D7@webweaving.org> <b74e2e97-3fd3-d24a-3844-4b6ffef821d1@mozilla.com> <36DA5C85-D4D9-4257-9050-304E0BB2C714@webweaving.org> <7cd1750c-0c5f-42b8-6608-9287d594079f@mozilla.com> <B785B482-9469-4BC7-BF77-58B603B30455@eguy.org>
X-Mailer: Apple Mail (2.3654.100.0.2.22)
X-Greylist: Sender succeeded SMTP AUTH, not delayed by milter-greylist-4.6.2 (weser.webweaving.org [148.251.234.232]); Thu, 12 Aug 2021 10:18:52 +0200 (CEST)
Archived-At: <https://mailarchive.ietf.org/arch/msg/urn/vIrnqasxBLhFGSzmF2xLRl0oVEE>
Subject: Re: [urn] Request for a Namespace Registration for Unique (Vaccination) Certificate Identifier
X-BeenThere: urn@ietf.org
X-Mailman-Version: 2.1.29
Precedence: list
List-Id: Revisions to URN RFCs <urn.ietf.org>
List-Unsubscribe: <https://www.ietf.org/mailman/options/urn>, <mailto:urn-request@ietf.org?subject=unsubscribe>
List-Archive: <https://mailarchive.ietf.org/arch/browse/urn/>
List-Post: <mailto:urn@ietf.org>
List-Help: <mailto:urn-request@ietf.org?subject=help>
List-Subscribe: <https://www.ietf.org/mailman/listinfo/urn>, <mailto:urn-request@ietf.org?subject=subscribe>
X-List-Received-Date: Thu, 12 Aug 2021 08:20:32 -0000

On 11 Aug 2021, at 19:57, Ed Guy <edguy@eguy.org> wrote:

>     >>> The UVCI pertains to a specific (medical) record about a specific
>     >>> person’s vaccination, test or recovery at event level [1,2]. This
>     >>> record is subject to national legislation and regulation.
>  
> #Pedantic mode on
> While you're updating this section, you probably should include the broader term
> 'immunization' although in the last year the terms have become nearly interchangeable.

Grin :) danger territory here :). I'll check with the medical expert - but suspect that given that the URN defines a fact about what happend (the application of a product (vaccine) that stimulates the immune system to produce immunity to a specific disease,